(Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's all-oral hepatitis C drug, clearing the way for the company to increase its revenue from sales of treatments for the liver-destroying viral infection.
via Reuters: Health News Read More Here..
No comments:
Post a Comment